Bringing the Oncology Community Together

Dr. Kudchadkar on BRAF and MEK Inhibitors in Melanoma

Ragini Kudchadkar, MD
Published Online: Friday, October 4, 2013
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

Early data demonstrated that the combination of BRAF and MEK inhibitors improve outcomes compared with single agents in patients with melanoma, Kudchadkar says.

If only one pathway is blocked, Kudchadkar says, the cancer cell figures out how to overcome the blockage with time. By combining the agents, the mechanism of resistance from the cancer cell is blocked. This allows patients to stay on therapy longer and decreases skin toxicities that are seen in single agent use.

Kudchadkar believes that it is likely that the combination will become the next standard of care.

Related Articles
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
T-VEC Promotes Tumor Shrinkage in Unresectable Melanoma
The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions
Nivolumab Delivers Durable Remissions With Low Toxicity in Advanced Melanoma
Nivolumab, a PD-1-specific antibody, has been shown to produce long-term remissions with limited toxicity in patients with advanced melanoma, according to results from one of the longest follow ups to examine the drug.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.